Irwin Naturals Refocuses on Core Business
Company Announcements

Irwin Naturals Refocuses on Core Business

Irwin Naturals Inc (TSE:IWIN) has released an update.

Irwin Naturals Inc. has announced the closure of its ketamine clinic division to refocus on its core business of botanical supplements, a sector that has been central to the brand for over two decades. The company also revealed changes in executive positions with Mark Green replacing Sean Sand as CFO, and the board of directors seeing the departure of Rod Kight and Sheri Orlowitz, with new members Luke Lokhorst and Lyle Maxson taking their places.

For further insights into TSE:IWIN stock, check out TipRanks’ Stock Analysis page.

Related Articles
GlobeNewswireIrwin Naturals Reports Q3 2023 Financial Results
TheFlyIrwin Naturals price target lowered to $3.00 from $4.50 at Roth MKM
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!